Published in Diabetes Care on January 09, 2008
Are health-related quality-of-life and self-rated health associated with mortality? Insights from Translating Research Into Action for Diabetes (TRIAD). Prim Care Diabetes (2009) 1.36
Self-rated health and mortality in individuals with diabetes mellitus: prospective cohort study. BMJ Open (2012) 1.03
Self-rated health and public health: a critical perspective. Front Public Health (2013) 1.02
The impact of decision aids to enhance shared decision making for diabetes (the DAD study): protocol of a cluster randomized trial. BMC Health Serv Res (2012) 0.96
Fatness and fitness: how do they influence health-related quality of life in type 2 diabetes mellitus? Health Qual Life Outcomes (2008) 0.94
Predictors of mortality of patients newly diagnosed with clinical type 2 diabetes: a 5-year follow up study. BMC Endocr Disord (2010) 0.94
The relationship between HbA1c level, symptoms and self-rated health in type 2 diabetic patients. Scand J Prim Health Care (2011) 0.93
Testing covariates of Type 2 diabetes-cognition associations in older adults: moderating or mediating effects? Neuropsychology (2010) 0.88
Factors related to perceived diabetes control are not related to actual glucose control for minority patients with diabetes. Diabetes Care (2010) 0.85
Change in self-rated general health is associated with perceived illness burden: a 1-year follow up of patients newly diagnosed with type 2 diabetes. BMC Public Health (2015) 0.81
Determinants of Poor Self-rated Health in Korean Adults With Diabetes. J Prev Med Public Health (2015) 0.75
Determinants of self-rated health in an Irish deprived suburban population - a cross sectional face-to-face household survey. BMC Public Health (2016) 0.75
A competing-risk-based score for predicting twenty-year risk of incident diabetes: the Beijing Longitudinal Study of Ageing study. Sci Rep (2016) 0.75
Evaluating the sensitivity of EQ-5D in a sample of patients with type 2 diabetes mellitus in two tertiary health care facilities in Nigeria. BMC Res Notes (2016) 0.75
Prediction of the 20-year incidence of diabetes in older Chinese: Application of the competing risk method in a longitudinal study. Medicine (Baltimore) (2016) 0.75
Baseline Quality of Life and Risk of Stroke in the ALLHAT Study (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). Stroke (2017) 0.75
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
Cetuximab for the treatment of colorectal cancer. N Engl J Med (2007) 13.39
Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med (2013) 11.10
Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol (2011) 5.94
Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol (2005) 5.40
Monitoring cholesterol levels: measurement error or true change? Ann Intern Med (2008) 3.35
Allocation concealment and blinding: when ignorance is bliss. Med J Aust (2005) 2.85
Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care (2003) 2.82
When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials? Ann Intern Med (2006) 2.59
Determining the sample size in a clinical trial. Med J Aust (2002) 2.51
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med (2003) 2.47
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol (2005) 2.25
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol (2010) 2.23
Sex differences in mortality following acute coronary syndromes. JAMA (2009) 2.17
Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. J Natl Cancer Inst (2010) 2.12
Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis. Eur Heart J (2006) 2.12
The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. Am J Med (2002) 2.09
Inclusion of patients in clinical trial analysis: the intention-to-treat principle. Med J Aust (2003) 2.06
Depression and cardiovascular morbidity and mortality: cause or consequence? Eur Heart J (2003) 2.00
Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Med Decis Making (2006) 1.89
Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet (2009) 1.88
Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncol (2007) 1.74
Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA (2012) 1.71
Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus. Clin Cancer Res (2012) 1.67
Prevalence of diagnosed and undiagnosed diabetes and prediabetes in New Zealand: findings from the 2008/09 Adult Nutrition Survey. N Z Med J (2013) 1.61
Patients with prolonged ischemic chest pain and presumed-new left bundle branch block have heterogeneous outcomes depending on the presence of ST-segment changes. J Am Coll Cardiol (2005) 1.58
The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. Eur Heart J (2008) 1.57
Ethics and statistics in randomized clinical trials. Stat Sci (1991) 1.49
Statistical methods in clinical trials. Med J Aust (2003) 1.47
Lessons learned from a clinical trial. Circulation (2004) 1.46
Development of life-expectancy tables for people with type 2 diabetes. Eur Heart J (2008) 1.44
Putting results of a clinical trial into perspective. Med J Aust (2007) 1.42
Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin. J Hypertens (2002) 1.42
Subgroup analysis in clinical trials. Med J Aust (2004) 1.42
Randomisation in clinical trials. Med J Aust (2002) 1.40
New Zealand Diabetes Cohort Study cardiovascular risk score for people with Type 2 diabetes: validation in the PREDICT cohort. J Prim Health Care (2012) 1.40
How fair is Medicare? The income-related distribution of Medicare benefits with special focus on chronic care items. Med J Aust (2012) 1.39
Can the prevalence of diagnosed diabetes be estimated from linked national health records? The validity of a method applied in New Zealand. J Prim Health Care (2011) 1.39
Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol (2011) 1.29
Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. J Am Coll Cardiol (2008) 1.26
Specifying objectives and outcomes for clinical trials. Med J Aust (2002) 1.24
Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Eur Heart J (2009) 1.17
Derivation and validation of a new cardiovascular risk score for people with type 2 diabetes: the new zealand diabetes cohort study. Diabetes Care (2010) 1.13
Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int Suppl (2004) 1.12
Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetes. Med Care (2009) 1.12
Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol (2002) 1.10
Cost-effectiveness of rehabilitation after an acute coronary event: a randomised controlled trial. Med J Aust (2005) 1.08
Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models. Diabetes (2012) 1.08
Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care (2011) 1.08
Estimating equations to correct self-reported height and weight: implications for prevalence of overweight and obesity in Australia. Aust N Z J Public Health (2008) 1.05
Challenges and opportunities for the Pharmaceutical Benefits Scheme. Med J Aust (2012) 1.05
Change in bias in self-reported body mass index in Australia between 1995 and 2008 and the evaluation of correction equations. Popul Health Metr (2011) 1.04
Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. Cardiovasc Diabetol (2011) 1.02
International variation in the use of evidence-based medicines for acute coronary syndromes. Eur Heart J (2003) 0.98
Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer. J Natl Cancer Inst (2011) 0.96
Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort. Diabetes Care (2012) 0.95
Outcomes of Two Trials of Oxygen-Saturation Targets in Preterm Infants. N Engl J Med (2016) 0.95
Baseline data in clinical trials. Med J Aust (2003) 0.95
Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes. Circulation (2002) 0.94
Cardiovascular disease on a global scale: defining the path forward for research and practice. Eur Heart J (2007) 0.92
The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial. Eur J Endocrinol (2013) 0.91
Estimating utility values for health states of overweight and obese individuals using the SF-36. Qual Life Res (2005) 0.91
An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes (2013) 0.90
Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study. J Am Heart Assoc (2013) 0.89
Rates and predictors of risk of stroke and its subtypes in diabetes: a prospective observational study. J Neurol Neurosurg Psychiatry (2012) 0.89
A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation. Qual Life Res (2011) 0.89
Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial. Arch Intern Med (2007) 0.89
Multiple analyses in clinical trials: sound science or data dredging? Med J Aust (2004) 0.89
White blood cell count predicts reduction in coronary heart disease mortality with pravastatin. Circulation (2005) 0.88
Statin use and sex-specific stroke outcomes in patients with vascular disease. Stroke (2006) 0.88
Derivation and validation of a renal risk score for people with type 2 diabetes. Diabetes Care (2013) 0.87
Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate. Arterioscler Thromb Vasc Biol (2009) 0.87
Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancer. Patient Educ Couns (2008) 0.87
Understanding the new HbA1c units for the diagnosis of Type 2 diabetes. N Z Med J (2012) 0.86
Generalising the results of trials to clinical practice. Med J Aust (2004) 0.86
Mortality and morbidity reduction by primary percutaneous coronary intervention is independent of the patient's age. JACC Cardiovasc Interv (2010) 0.86
Exploratory analysis of cardiac biomarkers in women with normal cardiac function receiving trastuzumab for breast cancer. Asia Pac J Clin Oncol (2011) 0.85
Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes. J Clin Endocrinol Metab (2012) 0.85
Using patient management as a surrogate for patient health outcomes in diagnostic test evaluation. BMC Med Res Methodol (2012) 0.84
Biases in the identification of risk factor thresholds and J-curves. Am J Epidemiol (2007) 0.84
Cost-effectiveness of artemisinin combination therapy for uncomplicated malaria in children: data from Papua New Guinea. Bull World Health Organ (2011) 0.84
Linking the evidence: intermediate outcomes in medical test assessments. Int J Technol Assess Health Care (2012) 0.84
The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia (2014) 0.83
Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. Circulation (2007) 0.83
Molecular biomarkers to individualise treatment: assessing the evidence. Med J Aust (2009) 0.83
The benefits and costs of tamoxifen for breast cancer prevention. Aust N Z J Public Health (2003) 0.82
Balloon warming time is the strongest predictor of late pulmonary vein electrical reconnection following cryoballoon ablation for atrial fibrillation. Heart Rhythm (2013) 0.82
Clinical trials and "real-world" medicine. Trial evidence best informs real-world medicine when it is relevant to the clinical problem. Med J Aust (2002) 0.82
Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Am Heart J (2012) 0.82
Simulating lifetime outcomes associated with complications for people with type 1 diabetes. Pharmacoeconomics (2013) 0.81
Life expectancy in individuals with type 2 diabetes: implications for annuities. Med Decis Making (2009) 0.81